Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175785 | 1.00 | PLG (0.47) | PLGPLATLMNAKMT2AMEN1 | |
| SCHEMBL18971850 | 1.00 | PLG (0.47) | PLGPLATLMNAKMT2AMEN1 | |
| SCHEMBL17893373 | 0.89 | PLG (0.40) | PLGPLATLMNAKMT2AMEN1 | |
| SCHEMBL2721040 | 0.88 | — | — | |
| SCHEMBL28464765 | 0.85 | KMT2A (0.54) | KMT2AMEN1GAAMGAMSI | |
| SCHEMBL7782689 | 0.85 | MGAM (0.43) | KMT2AMEN1GAAMGAMSI | |
| SCHEMBL5503853 | 0.84 | KMT2A (0.43) | KMT2AMEN1GAAMGAMSI | |
| SCHEMBL5503855 | 0.84 | KMT2A (0.43) | KMT2AMEN1GAAMGAMSI | |
| SCHEMBL14389978 | 0.82 | MGAM (0.44) | LMNAKMT2AMEN1GAAMGAM | |
| SCHEMBL14389976 | 0.82 | MGAM (0.44) | LMNAKMT2AMEN1GAAMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3609888-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4596041-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-110637015-B | Fanisole X receptor agonist and application thereof | 奥加诺沃公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220054469-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| CN-101052621-A | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | PFIZER PROD INC (US) | 2007-10-10 | — | — | CN | disclosed |
| EP-1829858-A2 | Dibenzylamine compounds and pharmaceutical use thereof | Japan Tobacco, Inc. (JP) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007081571-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1799648-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | Pfizer Products Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1533292-B1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2007-02-14 | — | — | EP | disclosed |
| US-20060247272-A1 | 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds | PFIZER INC | 2006-11-02 | — | — | US | disclosed |
| WO-2006033002-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | PFIZER INC | 2006-03-23 | — | — | US | disclosed |
| EP-1533292-A1 | DIBENZYLAMINE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054469-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | PLG 2817/4885PLAT 1488/4885LMNA 1148/4885 |
| US-20050059810-A1 | Dibenzylamine compound and medicinal use thereof | CETP, CES1, APOB | PLG 3017/4885PLAT 2888/4885LMNA 1556/4885 |
| US-20220089575-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | PLG 2817/4885PLAT 1488/4885LMNA 1148/4885 |
| US-20060247272-A1 | 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds | APOB, LDLR, CETP | PLG 1043/4885PLAT 705/4885LMNA 428/4885 |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | APOB, LDLR, CETP | PLG 1043/4885PLAT 705/4885LMNA 428/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | PLG 2517/4885PLAT 4417/4885LMNA 3498/4885 |
| US-11236071-B1 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | PLG 2817/4885PLAT 1488/4885LMNA 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.